Clare McCann

Search results

• 2023

  SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies

  Cox, M., Peacock, T. P., Harvey, W. T., Hughes, J., Wright, D. W., The COVID-19 Genomics UK (COG-UK) Consortium, Willett, B. J., Thomson, E., Gupta, R. K., Peacock, S. J., Robertson, D. L., Carabelli, A. M., Smith, D. L., Bashton, M., Young, G. R., McCann, C. M., Nelson, A., Crown, M., Henderson, J. H., Hollis, A., & 2 othersStanley, W. & Yew, W. C., 1 Feb 2023, In: Nature Reviews Microbiology. 21, 2, p. 112-124 13 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Neutralization 100%
  • Monoclonal Antibodies 80%
  • Severe Acute Respiratory Syndrome Coronavirus 2 80%
  • Epitope 60%
  • Mutation 60%
  160 Citations (Scopus)
• 2021

  SARS-CoV-2 variants, spike mutations and immune escape

  Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., Peacock, S. J., Robertson, D. L., The COVID-19 Genomics UK (COG-UK) Consortium, Bashton, M., Smith, D., Nelson, A., Young, G. & McCann, C., 1 Jul 2021, In: Nature Reviews Microbiology. 19, 7, p. 409-424 16 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  File

  • Severe Acute Respiratory Syndrome Coronavirus 2 100%
  • Mutation 83%
  • Virus 33%
  • Vaccine Efficacy 33%
  • Immunity 33%
  2321 Citations (Scopus)

  30 Downloads (Pure)